scispace - formally typeset
S

Sylke Müller

Researcher at University of Glasgow

Publications -  91
Citations -  10791

Sylke Müller is an academic researcher from University of Glasgow. The author has contributed to research in topics: Plasmodium falciparum & Thioredoxin. The author has an hindex of 47, co-authored 91 publications receiving 9551 citations. Previous affiliations of Sylke Müller include Bernhard Nocht Institute for Tropical Medicine & Life Sciences Institute.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis

Jane M. Carlton, +64 more
- 12 Jan 2007 - 
TL;DR: The genome sequence of the protist Trichomonas vaginalis predicts previously unknown functions for the hydrogenosome, which support a common evolutionary origin of this unusual organelle with mitochondria.
Journal ArticleDOI

Thioredoxin reductase as a pathophysiological factor and drug target

TL;DR: The hypothesis that TrxR and extracellular thioredoxin play a pathophysiologic role in chronic diseases such as rheumatoid arthritis, Sjögren's syndrom, AIDS, and certain malignancies, is substantiated by biochemical, virological, and clinical evidence.
Journal ArticleDOI

Complete Dna-Sequence Of Yeast Chromosome-Xi

Bernard Dujon, +112 more
- 02 Jun 1994 - 
TL;DR: The complete DNA sequence of the yeast Saccharomyces cerevisiae chromosome XI has been determined, and the 666,448-base-pair sequence has revealed general chromosome patterns.
Journal ArticleDOI

Thioredoxin reductase two modes of catalysis have evolved.

TL;DR: It is hoped that the chemical difference between the two high Mr forms of thioredoxin reductase may be exploited for drug design.